The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESMO 2019 | R/R DLBCL challanges: novel therapeutics
Jarrod Longcor
• 28 Sep 2019
Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, discusses the challenges of designing therapies for R/R diffuse large B-cell lymphoma (DLBCL) and these may be overcome. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
